BBNX

Beta Bionics, Inc. Common Stock
NASDAQHEALTHCAREMEDICAL DEVICES

Key Statistics

Market Cap
$853.56M
P/E Ratio
—
EPS
$-1.83
Beta
—
52W High
$32.71
52W Low
$8.80
50-Day MA
$18.83
200-Day MA
$14.78
Dividend Yield
—
Profit Margin
-65.30%
Forward P/E
—
PEG Ratio
—

About Beta Bionics, Inc. Common Stock

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. The company is headquartered in Irvine, California.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$127.27M
Gross Profit (TTM)$74.61M
EBITDA$-89.86M
Operating Margin-74.90%
Return on Equity-23.90%
Return on Assets-15.00%
Revenue/Share (TTM)$2.83
Book Value$7.38
Price-to-Book2.10
Price-to-Sales (TTM)6.71
EV/Revenue4.774
EV/EBITDA—
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)30.30%
Shares Outstanding$54.37M
Float$42.14M
% Insiders0.78%
% Institutions109.72%

Historical Volatility

HV 10-Day
134.66%
HV 20-Day
104.27%
HV 30-Day
87.39%
HV 60-Day
83.87%
HV Rank
—

Volatility is currently expanding

Analyst Ratings

Consensus ($25.10 target)
2
Strong Buy
9
Buy
4
Hold

Latest News

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Beta Bionics, Inc. of Class Action Lawsuit and Upcoming Deadlines – BBNX

NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

GlobeNewsWire11/3/2026Neutral
BBNX Deadline: BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud Lawsuit

NEW YORK, Nov. 3, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Beta Bionics, Inc. (NASDAQ: BBNX) between July 30, 2025 and February 24, 2026, both dates inclusive (the "Class Period"), of the important November 3, 2026 lead plaintiff deadline. So what: If you purchased Beta Bionics common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

PRNewsWire11/3/2026Neutral
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Beta Bionics (NASDAQ: BBNX) Investors of Securities Class Action Lawsuit Deadline on November 3, 2026

NEW YORK--(BUSINESS WIRE)---- $BBNX #BBNX--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) and reminds investors of the November 3, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. Th.

Business Wire11/3/2026Neutral
Beta Bionics, Inc. (NASDAQ:BBNX) SHAREHOLDER ALERT: Investors With Losses May Seek to Lead the Class Action in Beta Bionics, Inc. Securities Lawsuit - Contact Portnoy Law Firm

LOS ANGELES, Nov. 03, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm notifies investors in Beta Bionics, Inc. (NASDAQ: BBNX) that a securities class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026, inclusive (the 'Class Period'). Find out if you qualify to recover your per-share losses by choosing to join the class action and submit your trade details.

GlobeNewsWire11/3/2026Neutral
Beta Bionics Announces Participation at Upcoming Investor Conferences

IRVINE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will participate at upcoming investor conferences: Members of the Company's management team will present at the Wolfe Research 8th Annual Healthcare Conference on Tuesday, November 10, 2026 at 12:40pm Eastern Time.

GlobeNewsWire11/3/2026Neutral
BBNX FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important November 3 Deadline in Securities Class Action - BBNX

New York, New York--(Newsfile Corp. - November 2, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Beta Bionics, Inc. (NASDAQ: BBNX) between July 30, 2025 and February 24, 2026, both dates inclusive (the "Class Period"), of the important November 3, 2026 lead plaintiff deadline. SO WHAT: If you purchased Beta Bionics common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Newsfile Corp11/3/2026Neutral
BBNX FINAL DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important November 3 Deadline in Securities Class Action - BBNX

NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Beta Bionics, Inc. (NASDAQ: BBNX) between July 30, 2025 and February 24, 2026, both dates inclusive (the “Class Period”), of the important November 3, 2026 lead plaintiff deadline.

GlobeNewsWire11/3/2026Neutral
BBNX FINAL DEADLINE ALERT: Beta Bionics Investors with Losses Encouraged to Contact Hagens Berman Before Nov. 3rd Deadline in Securities Class Action

San Francisco, California--(Newsfile Corp. - November 2, 2026) - Hagens Berman reminds investors in Beta Bionics, Inc. (NASDAQ: BBNX) of the pending securities class action lawsuit and upcoming November 3, 2026 lead plaintiff deadline under the Private Securities Litigation Reform Act (PSLRA). Investors who suffered substantial losses purchasing Beta Bionics stock during the Class Period between July 30, 2025 and February 24, 2026, inclusive, are encouraged to submit your losses now to Hagens Berman to discuss their legal options.

Newsfile Corp11/2/2026Neutral
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Beta Bionics (NASDAQ: BBNX) Investors of Securities Class Action Lawsuit Deadline on November 3, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner  James (Josh) Wilson Encourages Investors Who Suffered Losses In Beta Bionics To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Beta Bionics between July 30, 2025 and February 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) and reminds investors of the November 3, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

GlobeNewsWire11/2/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BBNX and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 11/7/2026